Dibutyl hydrogen phosphate

Specific investigations: other studies

Administrative data

Endpoint:

endocrine system modulation

Type of information:

experimental study

Adequacy of study:

other information

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

study well documented, meets generally accepted scientific principles, acceptable for assessment

Data source

Reference

Reference Type:

publication

Title:

Structure-Oriented Research on the Antiestrogenic Effect of Organophosphate Esters and the Potential Mechanism

Author:

Li J

Bibliographic source:

Environ. Sci. Technol. 2020, 54, 14525−14534

Materials and methods

Principles of method if other than guideline:

E-screen assay in MCF-7 cells; transactivation assay in MVLN cells

Type of method:

in vitro

Endpoint addressed:

other: estrogenic and antiestrogenic effects

Test material

Test material information

Constituent 1

Reference substance name:

Dibutyl hydrogen phosphate

EC Number:

203-509-8

EC Name:

Dibutyl hydrogen phosphate

Cas Number:

107-66-4

Molecular formula:

C8H19O4P

IUPAC Name:

dibutyl hydrogen phosphate

Results and discussion

Any other information on results incl. tables

Dibutyl phosphate (DBP) was tested for estrogenic-like and/or antiestrogenic activity in the E-screen assay (cotreated with E2) in MCF-7 cells with an EC50 value of 127 µM, compared to the positive control E2 that induced proliferation in a dose-related manner with EC50 of 11.8 nN. In the transactivation assay in MVLN cells, to investigate further estrogenic receptor activity, with single exposure and cotreatment with E2 DBP could inhibit the luciferase activities in a dose-related manner, however with EC50 of 2 mM and 9.7 mM, respectively. E2 was used as positive control, and it showed an EC50 value of 79.7 pM.
Thus, no relevant estrogenic or antiestrogenic effects became obvious for DBP.